Are there any safety or efficacy data regarding the use of checkpoint inhibitors in patients on hemodialysis for ESRD?

What about as combined modality therapy with chemoRT?

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

Would you offer empiric lung SBRT for two growing FDG-avid lung lesions in a patient with severe COPD on oxygen?

What high-risk features for stage I NSCLC would lead you to consider adjuvant osimertinib?

Would you recommend adjuvant immunotherapy after platinum-based chemotherapy for patients with in resected NSCLC with HER2 mutations?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.